scholarly journals Altered intestinal microbiota–host mitochondria crosstalk in new onset Crohn’s disease

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Walid Mottawea ◽  
Cheng-Kang Chiang ◽  
Marcus Mühlbauer ◽  
Amanda E. Starr ◽  
James Butcher ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Laura Sanchis-Artero ◽  
Juan Francisco Martínez-Blanch ◽  
Sergio Manresa-Vera ◽  
Ernesto Cortés-Castell ◽  
Marina Valls-Gandia ◽  
...  

AbstractIntestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects. This prospective multicenter observational study involved 27 CD patients initiating anti-TNF treatment and 16 healthy individuals. Inflammatory activity was determined at baseline, 3 and 6 months, classifying patients into responders and non-responders. Fecal microbiota was analyzed by massive genomic sequencing thought 16S rRNA amplicon sequencing before and after six months of anti-TNF treatment. The CD cohort showed a decrease in genera of the class Clostridia, short-chain fatty acid producers, and an increase in the phylum Proteobacteria (p < 0.01) versus the healthy cohort. After anti-TNF treatment, the phylum Proteobacteria also increased in non-responders versus responders (13/27) (p < 0.005), with the class Clostridia increasing. In addition, alpha diversity increased in responders versus non-responders (p < 0.01), tending towards eubiosis. An association was found (p < 0.001) in the F.prausnitzii/E.coli ratio between responders and non-responders. The F/E ratio was the most accurate biomarker of anti-TNF response (area under the curve 0.87). Thus, anti-TNF treatment allows partial restoration of intestinal microbiota in responders and the F.prausnitzii/E.coli ratio can provide a reliable indicator of response to anti-TNF in CD.


2014 ◽  
Vol 15 (3) ◽  
pp. 382-392 ◽  
Author(s):  
Dirk Gevers ◽  
Subra Kugathasan ◽  
Lee A. Denson ◽  
Yoshiki Vázquez-Baeza ◽  
Will Van Treuren ◽  
...  

Gut Pathogens ◽  
2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Mohammad I. El Mouzan ◽  
Harland S. Winter ◽  
Assad A. Assiri ◽  
Kirill S. Korolev ◽  
Ahmad A. Al Sarkhy ◽  
...  

2018 ◽  
Vol 48 (11-12) ◽  
pp. 1242-1250 ◽  
Author(s):  
Tomer Ziv-Baran ◽  
Séamus Hussey ◽  
Malgorzata Sladek ◽  
Jorge Amil Dias ◽  
Javier Martin de Carpi ◽  
...  

2021 ◽  
Author(s):  
Xiufang Cui ◽  
Haiyang Wang ◽  
Ziping Ye ◽  
Yi Li ◽  
Xinyun Qiu ◽  
...  

Abstract BACKGROUND: The intestinal microbiota is thought to be involved in the occurrence of Inflammatory Bowel Disease in remission (IBDR) with Irritable Bowel Syndrome (IBS)-type symptoms, but the specific distinct profile of these bacteria remains unclear. Therefore, the purpose of this research is to investigate this issue by conducting a cross-sectional study.METHODS: IBS patients were diagnosed according to Rome Ⅳ criteria, IBD diagnosed according to the criteria of European Crohn & Colitis Organization (ECCO), IBDR patients with IBS-type symptoms were defined according to related IBS-type symptoms meeting the Rome IV criteria in IBDR patients, and were included Crohn’s disease in remission (CDR) and ulcerative colitis in remission (UCR) based on Crohn’s Disease Activity Index (DAI) and Mayo Scoring System respectively. Healthy controls come from the physical examination center and exclude people with underlying diseases. All enrolled subjects were divided into six groups, as followed: Health Control, IBS, CDR with IBS-type symptoms (CDR-IBS+), CDR without IBS-type symptoms (CDR-IBS-), UCR-IBS+ and UCR-IBS-. We collected fresh fecal samples from all subjects and applied 16S rRNA sequencing analysis to detect the structure and diversity of the microbiota among different groups. RESULTS: A total of 97 subjects were included in this study, of which 18 were health controls, 34 IBS patients, 25 CDR and 20 UCR. The richness of intestinal microbiota in CDR-IBS-was significantly lower than that in the control and IBS groups based on the analysis of observed species and Chao index (P<0.05). The observed species index in CDR-IBS+ was significantly higher than CDR-IBS- group (median index: 254.8 vs 203, P=0.036). No difference was found in Alpha diversity between UCR-IBS+ and UCR-IBS-. At phylum level, there was no significant difference between UC or CD with IBS-type symptoms and those without related symptoms. At genus level, the number of Faecalibacterium in CDR-IBS+ increased significantly while Fusobacterium decreased compared with CDR-IBS-(mean relative abundance of Faecalibacterium: 20.35% vs 5.18%, P<0.05; Fusobacterium: 1.51% vs 5.2%, P<0.05). However, compared with UCR-IBS - group, the number of Faecalibacterium in UCR-IBS+ group decreased, while the number of Streptococcus increased, but there was no statistical difference in the genus structure. Regardless of the phylum or genus level, the abundance and composition of the microbiota of IBS patients were not distinct from those of healthy people.CONCLUSIONS: CD patients in remission with IBS-type symptoms may be related to the increase of Faecalibacterium and decrease of Fusobacterium. UC patients in remission with IBS-type symptoms cannot be explained by changes in the abundance and structure of intestinal microbiota from our across-sectional study.


2020 ◽  
Vol 158 (6) ◽  
pp. S-471
Author(s):  
Laura Sanchis ◽  
Sergio Manresa-Vera ◽  
Juan F. Martínez ◽  
Marina Valls Gandia ◽  
Marisa Iborra ◽  
...  

2014 ◽  
Vol 147 (4) ◽  
pp. 932-934 ◽  
Author(s):  
Lindsay J. Hall ◽  
John Walshaw ◽  
Alastair J.M. Watson

2014 ◽  
Vol 146 (5) ◽  
pp. S-836
Author(s):  
Monika Schaubeck ◽  
Thomas Clavel ◽  
Nadine Waldschmitt ◽  
Jan Wehkamp ◽  
Ines Martinez ◽  
...  

2009 ◽  
Vol 136 (5) ◽  
pp. A-361
Author(s):  
Yamile Zabana ◽  
Esther Garcia-Planella ◽  
Manuel Van Domselaar ◽  
Míriam Mañosa ◽  
Jordi Gordillo ◽  
...  

2015 ◽  
Vol 148 (4) ◽  
pp. S-61
Author(s):  
Monika Schaubeck ◽  
Thomas Clavel ◽  
Ilias Lagkouvardos ◽  
Jelena Calasan ◽  
Sven-Bastiaan Haange ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document